拥抱了针对心力衰竭的向组合疗法的时代,其中保留了喷射分数
Satoshi Shoji1,2, Stephen J Greene3,4, Robert J Mentz3,4
1Duke Clinical Research Institute, 300 W Morgan St, Durham, NC, 27701, USA. satoshi.shoji@duke.edu.
Heart failure reviews
|August 26, 2024
概括
四重疗法有利于心力衰竭,减少喷射分数的患者. 然而,心力衰竭的治疗与保存的喷射分数是复杂的,需要针对特定的患者子组的向组合疗法方法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 四重疗法为心力衰竭提供了一致的好处,心力衰竭的降低射出分数 (HFrEF).
- 对于心力衰竭的治疗效益与保存的喷射分数 (HFpEF) 是不一致的跨患者子组.
- 在HFpEF中的异质性使实践心脏病学家的治疗决策变得复杂.
研究的目的:
- 为了应对心力衰竭与保存的喷射分数 (HFpEF) 治疗的挑战.
- 为HFpEF提出"有针对性的"组合治疗策略.
- 在特定的HFpEF表型中优化基于证据的药物使用.
主要方法:
- 对HFpEF疗法的现有临床试验数据的审查.
- 对不同HFpEF亚组的治疗效益的分析.
- 基于表型的有针对性的治疗方法的开发.
主要成果:
- -葡萄糖共运输体2抑制剂在HFpEF中显示出一致的好处.
- ангиотензин受体-neprilysin抑制剂,矿物质皮质体受体对抗剂和GLP-1受体激动剂在特定的HFpEF表型中显示出好处.
- 治疗反应的变化凸显了个性化医疗的必要性.
结论:
- 一种"适合所有人"的方法不适合心力衰竭与保存的喷射分数 (HFpEF).
- 针对HFpEF亚组量身定制的向组合治疗可以优化临床结果.
- 该战略旨在改善HFpEF中基于证据的治疗方法的实施.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K